{"@type":"dcat:Dataset","accessLevel":"public","bureauCode":["009:10"],"contactPoint":{"fn":"openFDA","hasEmail":"mailto:open@fda.hhs.gov"},"description":"<p>The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks.</p>\n","identifier":"b532a731-9536-47fe-beb5-3cdd0b5f6428","keyword":["cder"],"language":["en"],"license":"http://opendefinition.org/licenses/odc-odbl/","modified":"2016-04-05","programCode":["009:002"],"publisher":{"@type":"org:Organization","name":"Department of Health &amp; Human Services"},"title":"Approved Risk Evaluation and Mitigation Strategies"}
